284 related articles for article (PubMed ID: 19909299)
1. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
2. Exploring c-Met kinase flexibility by sampling and clustering its conformational space.
Asses Y; Venkatraman V; Leroux V; Ritchie DW; Maigret B
Proteins; 2012 Apr; 80(4):1227-38. PubMed ID: 22275094
[TBL] [Abstract][Full Text] [Related]
3. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
4. Regulatory roles of the N-terminal domain based on crystal structures of human pyruvate dehydrogenase kinase 2 containing physiological and synthetic ligands.
Knoechel TR; Tucker AD; Robinson CM; Phillips C; Taylor W; Bungay PJ; Kasten SA; Roche TE; Brown DG
Biochemistry; 2006 Jan; 45(2):402-15. PubMed ID: 16401071
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
Keenan SM; Welsh WJ
J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
9. Transplant-insert-constrain-relax-assemble (TICRA): protein-ligand complex structure modeling and application to kinases.
Meshkat S; Klon AE; Zou J; Wiseman JS; Konteatis Z
J Chem Inf Model; 2011 Jan; 51(1):52-60. PubMed ID: 21117680
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL; McTigue MA; Ryan K; Cui J; Zou HY; Zhu JX; Chau F; Alton G; Karlicek S; Christensen JG; Murray BW
Biochemistry; 2009 Jun; 48(23):5339-49. PubMed ID: 19459657
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a RET TK catalytic domain by homology modeling.
Tuccinardi T; Manetti F; Schenone S; Martinelli A; Botta M
J Chem Inf Model; 2007; 47(2):644-55. PubMed ID: 17295463
[TBL] [Abstract][Full Text] [Related]
12. Molecular modeling and site-directed mutagenesis studies of a phorbol ester-binding site in protein kinase C.
Wang S; Kazanietz MG; Blumberg PM; Marquez VE; Milne GW
J Med Chem; 1996 Jun; 39(13):2541-53. PubMed ID: 8691452
[TBL] [Abstract][Full Text] [Related]
13. A new Met inhibitory-scaffold identified by a focused forward chemical biological screen.
Patané S; Pietrancosta N; Hassani H; Leroux V; Maigret B; Kraus JL; Dono R; Maina F
Biochem Biophys Res Commun; 2008 Oct; 375(2):184-9. PubMed ID: 18703015
[TBL] [Abstract][Full Text] [Related]
14. Inclining the purine base binding plane in protein kinase CK2 by exchanging the flanking side-chains generates a preference for ATP as a cosubstrate.
Yde CW; Ermakova I; Issinger OG; Niefind K
J Mol Biol; 2005 Mar; 347(2):399-414. PubMed ID: 15740749
[TBL] [Abstract][Full Text] [Related]
15. Homology models of the mutated EGFR and their response towards quinazoline analogues.
Kotra S; Madala KK; Jamil K
J Mol Graph Model; 2008 Oct; 27(3):244-54. PubMed ID: 18585943
[TBL] [Abstract][Full Text] [Related]
16. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
Traxler PM; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Med Chem; 1996 Jun; 39(12):2285-92. PubMed ID: 8691423
[TBL] [Abstract][Full Text] [Related]
17. Structure modeling, ligand binding, and binding affinity calculation (LR-MM-PBSA) of human heparanase for inhibition and drug design.
Zhou Z; Bates M; Madura JD
Proteins; 2006 Nov; 65(3):580-92. PubMed ID: 16972282
[TBL] [Abstract][Full Text] [Related]
18. [Progress in the design of selective ATP-competitive kinase inhibitors].
Deng XQ; Xiang ML; Jia R; Yang SY
Yao Xue Xue Bao; 2007 Dec; 42(12):1232-6. PubMed ID: 18338633
[TBL] [Abstract][Full Text] [Related]
19. Computational studies of tryptophanyl-tRNA synthetase: activation of ATP by induced-fit.
Kapustina M; Carter CW
J Mol Biol; 2006 Oct; 362(5):1159-80. PubMed ID: 16949606
[TBL] [Abstract][Full Text] [Related]
20. Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling.
Furlan A; Colombo F; Kover A; Issaly N; Tintori C; Angeli L; Leroux V; Letard S; Amat M; Asses Y; Maigret B; Dubreuil P; Botta M; Dono R; Bosch J; Piccolo O; Passarella D; Maina F
Eur J Med Chem; 2012 Jan; 47(1):239-54. PubMed ID: 22138308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
